分子腫瘤診斷市場－全球產業規模、佔有率、趨勢、競爭格局、機會、預測：按產品類型、技術、應用、癌症類型、最終用戶、地區和競爭格局分類，2021-2031年

全球分子腫瘤診斷市場預計將從 2025 年的 37.6 億美元成長到 2031 年的 83.9 億美元，複合年成長率為 14.31%。

在該領域，診斷技術透過分析體液和組織樣本中的特定分子（例如DNA、RNA和蛋白質）來檢測疾病的存在並評估風險，最終有助於制定治療方法、追蹤復發情況並評估治療效果。市場擴張的主要驅動力是全球癌症發病率的上升以及對需要精確分子分析的個人化醫療需求的不斷成長。此外，對早期診斷和全面風險評估的日益重視，以及分子診斷在臨床試驗中日益廣泛的應用，也促進了市場成長。為了佐證對先進診斷解決方案的持續需求，美國病理學家協會預測，到2026年，美國將新增超過200萬例癌症病例。

然而，最先進的分子檢測平台和設備的高昂成本是市場成長的主要障礙。除了這些龐大的資金需求外，新型基因組檢測的保險覆蓋範圍持續存在差異，這給開發中國家和小規模檢測實驗室帶來了沉重的負擔。因此，這些關鍵診斷技術的應用和整合受到了相當大的限制。

市場促進因素

全球癌症發生率的上升是分子腫瘤診斷市場的主要驅動力，推動了對先進工具的需求，以支持早期檢測、預後和治療決策。隨著世界人口老化和風險因素的變化，癌症的整體負擔持續加重，對先進診斷方案的需求也日益穩定。根據《柳葉刀》雜誌發表的一項研究（該研究被健康指標與評估研究所 (IHME) 在其 2025 年 9 月發布的《問答：全球癌症負擔及 2025 年預測》中引用），2023 年全球新增癌症病例超過 1800 萬例。如此龐大的診斷數量凸顯了對能夠準確識別癌症類型及其獨特分子特徵的分子檢測的迫切需求，這對於最佳化患者照護和持續監測至關重要。

此外，個人化和精準腫瘤學的日益普及也推動了市場成長。這些調查方法本質上依賴全面的分子譜分析，以根據每位患者的獨特特徵量身定做治療方法。因此，用於識別特定生物標記並促進標靶治療的伴隨診斷需求激增。領先的市場參與企業正在大力投資這項轉型，以滿足不斷成長的需求。在2025年4月BioSpace發表的一篇報導《羅氏未來五年將在美國製藥和診斷業務投資500億美元》中，羅氏透露了未來五年在美國投資500億美元的計劃，用於為其先進的診斷和醫療產品組合建立新的生產和研發設施。這項投資表明，分子數據正被深度整合到標準治療方案中。此外，羅氏的投資人數據顯示，到2025年，全球將進行310億次診斷測試，顯示診斷工具在現代醫學中的應用日益整體，在腫瘤學領域的重要性也日益凸顯。

市場挑戰

先進分子檢測設備和平台的高昂成本是全球分子腫瘤診斷檢查室擴張的主要障礙。購買此類先進設備所需的大量資本投入給檢查室帶來了沉重的經濟負擔，尤其是在開發中國家和小規模。此外，針對尖端基因組檢測的報銷政策長期存在缺陷，加劇了這個問題，使得醫療機構無法完全收回開展這些複雜且專業的診斷程序所產生的巨額成本。

這些財政限制直接阻礙了關鍵診斷技術進步的廣泛應用。美國臨床實驗室協會 (ACLA) 警告稱，除非國會介入，否則將於 2026 年 1 月 31 日生效的新臨床實驗室收費表可能會導致約 800 項檢測的報銷額度減少高達 15%。此類報銷額度的減少將威脅檢查室的財務穩定，並限制其資助新的分子腫瘤學檢測和擴展現有服務的能力。最終，這種情況將阻礙尖端診斷設備的應用，限制市場滲透率，並減緩整個分子腫瘤學診斷領域的發展速度。

市場趨勢

分子腫瘤診斷領域的一項決定性進展是次世代定序(NGS) 技術在全面基因組分析的廣泛應用。這一轉變的特點是，全面的基因組評估擴大融入標準臨床實踐中，超越了單基因評估，揭示了腫瘤的整體情況基因組成。全面的基因組分析有助於發現具有治療價值的突變，指導個別化治療性介入，並能更準確地理解疾病進展機制。為了佐證這一發展勢頭，1stOncology 於 2026 年 2 月 5 日報道稱，Illumina 公司 2025 年第四季度財報顯示，其在中國以外地區的臨床耗材銷售額成長了 20%。這一成長主要歸功於基於定序的診斷技術的日益普及。

另一項對產業產生重大影響的突破性趨勢是液態生物檢體在癌症治療非侵入性管理中的日益普及。透過檢測血液樣本中的循環腫瘤DNA和其他生物標記物，液態生物檢體為癌症診斷、治療反應追蹤和復發監測提供了比傳統組織切片檢查日益成長的臨床應用和實用性，Natera公司2025年第四季度的腫瘤檢測量較上年同期成長了54.7%，處理了約233,300份檢測樣本。 StockTitan於2026年2月26日發布的報告詳細闡述了該公司關於收入和現金流的8-K報告，其中也提到了這一情況。

目錄

第1章 產品概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球分子腫瘤診斷市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品類型（儀器、試劑盒/檢測、軟體）
  • 透過技術手段（螢光原位雜合反應（FISH）、次世代定序（NGS）、聚合酵素鏈鎖反應（PCR）、免疫組織化學（IHC）、流式細胞技術及其他技術）
  • 按應用領域（研究、臨床）
  • 癌症類型（{固體癌（乳癌、卵巢癌、攝護腺癌、肺癌、大腸直腸癌、其他固體癌）、血液系統癌症（淋巴瘤、白血病、多發性骨髓瘤、其他骨髓惡性腫瘤）}）
  • 依最終用戶（醫院/診斷中心、檢驗實驗室、製藥/生技公司、學術/研究機構）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美分子腫瘤診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲分子腫瘤診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區分子腫瘤診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲分子腫瘤診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲分子腫瘤診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球分子腫瘤診斷市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Sysmex Corporation
• F. Hoffmann-La Roche Ltd.
• Myriad Genetics, Inc.
• HTG Molecular Diagnostics, Inc.
• Danaher Corporation
• QIAGEN NV
• Bio-Rad Laboratories, Inc.
• Agilent Technologies, Inc.
• Illumina, Inc.
• Bayer AG

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Molecular Oncology Diagnostics Market is anticipated to expand from USD 3.76 billion in 2025 to USD 8.39 billion by 2031, reflecting a compound annual growth rate of 14.31%. This field involves laboratory techniques designed to detect disease presence and assess risk by analyzing specific molecules like DNA, RNA, and proteins in fluid or tissue samples, ultimately aiding in treatment formulation, recurrence tracking, and evaluating therapy effectiveness. Market advancement is largely driven by rising global cancer rates and a surging need for personalized medicine, which requires accurate molecular profiling. Expansion is additionally bolstered by a growing emphasis on early diagnosis, thorough risk assessment, and the incorporation of molecular diagnostics within clinical trials. Highlighting the ongoing demand for sophisticated diagnostic solutions, the College of American Pathologists projects that the United States will see over two million new cancer cases in 2026.

However, the high expenses linked to cutting-edge molecular testing platforms and equipment pose a major obstacle to market growth. These significant financial requirements, combined with ongoing gaps in reimbursement coverage for novel genomic assays, place a disproportionate burden on developing nations and smaller laboratories. As a result, the widespread availability and integration of these vital diagnostic technologies are considerably limited.

Market Driver

Rising cancer rates worldwide serve as a primary catalyst for the molecular oncology diagnostics market, driving the need for sophisticated tools to assist in early detection, prognosis, and treatment direction. As global demographics shift toward aging populations and risk factor exposures change, the overall cancer burden continues to grow, fostering a steady requirement for advanced diagnostic options. Research featured in The Lancet and referenced by the Institute for Health Metrics and Evaluation in its September 2025 publication, "Q&A: Global burden of cancer and forecasts to 2025," noted over 18 million new cancer cases globally in 2023. This immense volume of diagnoses emphasizes the vital necessity for molecular testing capable of precisely characterizing cancer types and their unique molecular signatures, a critical component for optimizing patient care and ongoing monitoring.

Market growth is additionally fueled by the increasing embrace of personalized and precision oncology, methodologies that depend intrinsically on comprehensive molecular profiling to customize therapies based on a patient's distinct traits. Consequently, there is a surging need for companion diagnostics designed to pinpoint specific biomarkers and facilitate targeted treatments. Major industry participants are directing substantial capital toward this transition to accommodate the rising demand. In an April 2025 BioSpace article titled 'Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years,' Roche revealed plans to channel USD 50 billion into the U.S. over five years to establish new manufacturing and research facilities for its advanced diagnostics and medical portfolio. This investment demonstrates how deeply molecular data is becoming embedded in standard treatment protocols. Moreover, Roche's investor data indicates that 31 billion diagnostic tests were supplied globally in 2025, illustrating the widespread utilization of diagnostic tools across modern healthcare and their escalating relevance in the field of oncology.

Market Challenge

High expenses tied to sophisticated molecular testing equipment and platforms act as a formidable hurdle to the expansion of the global molecular oncology diagnostics market. The massive capital investments required to secure such advanced machinery impose a heavy financial burden, especially on laboratories in developing nations and those operating on a smaller scale. Additionally, ongoing deficiencies in reimbursement policies for cutting-edge genomic assays worsen the situation, hindering healthcare providers from fully recouping the substantial expenses incurred while administering these intricate and specialized diagnostic procedures.

These monetary constraints directly hinder broad accessibility to vital diagnostic advancements. The American Clinical Laboratory Association warns that unless Congress intervenes, roughly 800 laboratory tests will face rate reductions of up to 15% under the Clinical Laboratory Fee Schedule starting January 31, 2026. Such cuts in reimbursement pose a threat to the financial stability of laboratories, limiting their ability to fund new molecular oncology tests or broaden their current offerings. Ultimately, this dynamic stifles the uptake of modern diagnostic instruments, limits market reach, and decelerates the overarching growth trajectory of the molecular oncology diagnostics sector.

Market Trends

A defining development in molecular oncology diagnostics is the widespread adoption of Next-Generation Sequencing (NGS) for extensive genomic profiling. This shift is marked by the growing incorporation of comprehensive genomic evaluations into standard clinical practice, transitioning away from single-gene assessments to deliver a complete picture of a tumor's genetic makeup. Thorough genomic profiling facilitates the discovery of actionable mutations, directs customized therapeutic interventions, and offers a more precise understanding of how the disease advances. Highlighting this momentum, 1stOncology reported on February 5, 2026, that Illumina's Q4 2025 earnings showed a 20% increase in clinical consumables revenue outside of China, a surge attributed to the wider embrace of sequencing-reliant diagnostics.

Another revolutionary trend heavily influencing the industry is the rising utilization of liquid biopsies for the non-invasive management of cancer. By examining circulating tumor DNA and other biomarkers in blood samples, liquid biopsies present a less intrusive substitute for conventional tissue biopsies when diagnosing cancer, tracking treatment efficacy, and monitoring for relapse. This approach is particularly advantageous when securing tissue samples is challenging or when continuous observation is necessary, granting immediate perspective on how a tumor is evolving. Demonstrating this rising clinical acceptance and practicality, Natera experienced a 54.7% year-over-year jump in its oncology test volume during the fourth quarter of 2025, processing roughly 233,300 tests, as noted in a February 26, 2026, Stock Titan report detailing the company's 8-K filing on revenue and cash flow.

Key Market Players

• Sysmex Corporation
• F. Hoffmann-La Roche Ltd.
• Myriad Genetics, Inc.
• HTG Molecular Diagnostics, Inc.
• Danaher Corporation
• QIAGEN N.V.
• Bio-Rad Laboratories, Inc.
• Agilent Technologies, Inc.
• Illumina, Inc.
• Bayer AG

Report Scope

In this report, the Global Molecular Oncology Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Molecular Oncology Diagnostics Market, By Product Type

• Instruments
• Kits and Assays
• Software

Molecular Oncology Diagnostics Market, By Technology

• Fluorescence In-Situ Hybridization (FISH)
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Immunohistochemistry (IHC)
• Flow Cytometry
• Other Technologies

Molecular Oncology Diagnostics Market, By Application

• Research
• Clinical

Molecular Oncology Diagnostics Market, By Cancer Type

• Solid Tumor
• Blood Cancers

Molecular Oncology Diagnostics Market, By End User

• Hospitals and Diagnostic Centers
• Reference Laboratories
• Pharmaceutical and Biotechnology Companies
• Academic
• Research Institutes

Molecular Oncology Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Molecular Oncology Diagnostics Market.

Available Customizations:

Global Molecular Oncology Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Molecular Oncology Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Instruments, Kits and Assays, Software)
  • 5.2.2. By Technology (Fluorescence In-Situ Hybridization (FISH), Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Flow Cytometry, Other Technologies)
  • 5.2.3. By Application (Research, Clinical)
  • 5.2.4. By Cancer Type ({Solid Tumor (Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Other Solid Tumors), Blood Cancers (Lymphoma, Leukemia, Multiple Myeloma,, other Hematological Malignancies)})
  • 5.2.5. By End User (Hospitals and Diagnostic Centers, Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic, Research Institutes)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Molecular Oncology Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By Cancer Type
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Molecular Oncology Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By Cancer Type
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Molecular Oncology Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By Cancer Type
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Molecular Oncology Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By Cancer Type
      • 6.3.3.2.5. By End User

7. Europe Molecular Oncology Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By Cancer Type
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Molecular Oncology Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By Cancer Type
      • 7.3.1.2.5. By End User
  • 7.3.2. France Molecular Oncology Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By Cancer Type
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Molecular Oncology Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By Cancer Type
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Molecular Oncology Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By Cancer Type
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Molecular Oncology Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By Cancer Type
      • 7.3.5.2.5. By End User

8. Asia Pacific Molecular Oncology Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By Cancer Type
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Molecular Oncology Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By Cancer Type
      • 8.3.1.2.5. By End User
  • 8.3.2. India Molecular Oncology Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By Cancer Type
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Molecular Oncology Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By Cancer Type
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Molecular Oncology Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By Cancer Type
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Molecular Oncology Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By Cancer Type
      • 8.3.5.2.5. By End User

9. Middle East & Africa Molecular Oncology Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By Cancer Type
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Molecular Oncology Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By Cancer Type
      • 9.3.1.2.5. By End User
  • 9.3.2. UAE Molecular Oncology Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By Cancer Type
      • 9.3.2.2.5. By End User
  • 9.3.3. South Africa Molecular Oncology Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By Cancer Type
      • 9.3.3.2.5. By End User

10. South America Molecular Oncology Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By Cancer Type
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Molecular Oncology Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By Cancer Type
      • 10.3.1.2.5. By End User
  • 10.3.2. Colombia Molecular Oncology Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By Cancer Type
      • 10.3.2.2.5. By End User
  • 10.3.3. Argentina Molecular Oncology Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By Cancer Type
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Molecular Oncology Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Sysmex Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. F. Hoffmann-La Roche Ltd.
• 15.3. Myriad Genetics, Inc.
• 15.4. HTG Molecular Diagnostics, Inc.
• 15.5. Danaher Corporation
• 15.6. QIAGEN N.V.
• 15.7. Bio-Rad Laboratories, Inc.
• 15.8. Agilent Technologies, Inc.
• 15.9. Illumina, Inc.
• 15.10. Bayer AG

16. Strategic Recommendations

17. About Us & Disclaimer